Trials / Recruiting
RecruitingNCT07403188
A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Kyverna Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this long-term follow-up (LTFU) study is to collect delayed adverse events (AEs) and understand the persistence of KYV-101 (autologous CAR T cell product; gene-modified product), in participants who have been administered KYV-101 (gene-modified product; autologous CAR T cell product). This LTFU protocol will be open to any participant who received at least one infusion of KYV-101 in a previous Kyverna sponsored clinical trial or Investigator Initiated Trial (IIT).
Conditions
- Refractory Lupus Nephritis
- Myasthaenia Gravis
- Stiff Person Syndrome
- Rheumatoid Arthritis (RA)
- Multiple Sclerosis
- Dermatomyositis
- Systemic Sclerosis (SSc)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KYV-101 | Autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) product. |
Timeline
- Start date
- 2025-11-24
- Primary completion
- 2041-01-01
- Completion
- 2041-01-01
- First posted
- 2026-02-11
- Last updated
- 2026-02-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07403188. Inclusion in this directory is not an endorsement.